Asian Pacific Journal of Cancer Prevention

Asian Pacific Journal of Cancer Prevention (아시아태평양암예방학회)
권호 표지
DOI QR코드

DOI QR Code

Serum Adiponectin but not Leptin at Diagnosis as a Predictor of Breast Cancer Survival

  • Lee, Sang-Ah (Department of Preventive Medicine, Kangwon National University School of Medicine) ;
  • Sung, Hyuna (Department of Biomedical Sciences, Seoul National University College of Medicine) ;
  • Han, Wonshik (Department of Surgery, Seoul National University College of Medicine) ;
  • Noh, Dong-Young (Department of Surgery, Seoul National University College of Medicine) ;
  • Ahn, Sei-Hyun (Department of Surgery, University of Ulsan College of Medicine and Asan Medical Center) ;
  • Kang, Daehee (Department of Biomedical Sciences, Seoul National University College of Medicine)
  • Published : 2014.08.15
Download PDF
⟨ Previous Next ⟩

Abstract

Limited numbers of epidemiological studies have examined the relationship between adipokines and breast cancer survival. Preoperative serum levels of obesity-related adipokines (leptin and adiponectin) were here measured in 370 breast cancer patients, recruited from two hospitals in Korea. We examined the association between those adipokines and disease-free survival (DFS). The TNM stage, ER status and histological grade were aslo assessed in relation to breast cancer survival. Elevated adiponectin levels were associated with reduced DFS of breast cancer ($P_{trend}=0.03$) among patients with normal body weight, predominantly in postmenopausal women. There was no association of leptin with breast cancer survival. In conclusion, our study suggests that high levels of adiponectin at diagnosis are associated with breast cancer survival among women with normal body weight.

Keywords

References

  1. Brakenhielm E, Veitonmaki N, Cao R, et al (2004). Adiponectininduced antiangiogenesis and antitumor activity involve caspase-mediated endothelial cell apoptosis. Proc Natl Acad Sci U S A, 101, 2476-81. https://doi.org/10.1073/pnas.0308671100
  2. Cauley JA, Gutai JP, Kuller LH, et al (1989). The epidemiology of serum sex hormones in postmenopausal women. Am J Epidemiol, 129, 1120-31.
  3. Chen DC, Chung YF, Yeh YT, et al (2006). Serum adiponectin and leptin levels in Taiwanese breast cancer patients. Cancer Lett, 237, 109-14. https://doi.org/10.1016/j.canlet.2005.05.047
  4. Cleary MP, Maihle NJ (1997). The role of body mass index in the relative risk of developing premenopausal versus postmenopausal breast cancer. Proc Soc Exp Biol Med, 216, 28-43. https://doi.org/10.3181/00379727-216-44153B
  5. Cust AE, Stocks T, Lukanova A, et al (2009). The influence of overweight and insulin resistance on breast cancer risk and tumour stage at diagnosis: a prospective study. Breast Cancer Res Treat, 113, 567-76. https://doi.org/10.1007/s10549-008-9958-8
  6. Dieudonne MN, Bussiere M, Dos Santos E, et al (2006). Adiponectin mediates antiproliferative and apoptotic responses in human MCF7 breast cancer cells. Biochem Biophys Res Commun, 345, 271-9. https://doi.org/10.1016/j.bbrc.2006.04.076
  7. Dieudonne MN, Machinal-Quelin F, Serazin-Leroy V, et al (2002). Leptin mediates a proliferative response in human MCF7 breast cancer cells. Biochem Biophys Res Commun, 293, 622-8. https://doi.org/10.1016/S0006-291X(02)00205-X
  8. Fisher FM, Trujillo ME, Hanif W, et al (2005). Serum high molecular weight complex of adiponectin correlates better with glucose tolerance than total serum adiponectin in Indo-Asian males. Diabetologia, 48, 1084-7. https://doi.org/10.1007/s00125-005-1758-7
  9. Fontana L, Eagon JC, Trujillo ME, et al (2007). Visceral fat adipokine secretion is associated with systemic inflammation in obese humans. Diabetes, 56, 1010-3. https://doi.org/10.2337/db06-1656
  10. Frankenberry KA, Skinner H, Somasundar P, et al (2006). Leptin receptor expression and cell signaling in breast cancer. Int J Oncol, 28, 985-93.
  11. Gadgil A, Roy N, Sankaranarayanan R, et al (2012). Effect of comprehensive breast care on breast cancer outcomes: a community hospital based study from Mumbai, India. Asian Pac J Cancer Prev, 13, 1105-9. https://doi.org/10.7314/APJCP.2012.13.4.1105
  12. Gaudet MM, Falk RT, Gierach GL, et al (2010). Do adipokines underlie the association between known risk factors and breast cancer among a cohort of United States women? Cancer Epidemiol, 34, 580-6. https://doi.org/10.1016/j.canep.2010.05.014
  13. Goodwin PJ, Ennis M, Fantus IG, et al (2005). Is leptin a mediator of adverse prognostic effects of obesity in breast cancer? J Clin Oncol, 23, 6037-42. https://doi.org/10.1200/JCO.2005.02.048
  14. Gross AL, Newschaffer CJ, Hoffman-Bolton J, et al (2013). Adipocytokines, inflammation, and breast cancer risk in postmenopausal women: a prospective study. Cancer Epidemiol Biomarkers Prev, 22, 1319-24. https://doi.org/10.1158/1055-9965.EPI-12-1444
  15. Gulcelik MA, Colakoglu K, Dincer H, et al (2012). Associations between adiponectin and two different cancers: breast and colon. Asian Pac J Cancer Prev, 13, 395-8. https://doi.org/10.7314/APJCP.2012.13.1.395
  16. Haghighat S, Akbari ME, Ghaffari S, et al (2012). Standardized breast cancer mortality rate compared to the general female population of Iran. Asian Pac J Cancer Prev, 13, 5525-8. https://doi.org/10.7314/APJCP.2012.13.11.5525
  17. Harris HR, Tworoger SS, Hankinson SE, et al (2011). Plasma leptin levels and risk of breast cancer in premenopausal women. Cancer Prev Res, 4, 1449-56. https://doi.org/10.1158/1940-6207.CAPR-11-0125
  18. Hou WK, Xu YX, Yu T, et al (2007). Adipocytokines and breast cancer risk. Chin Med J, 120, 1592-6.
  19. Hu X, Juneja SC, Maihle NJ, et al (2002). Leptin--a growth factor in normal and malignant breast cells and for normal mammary gland development. J Natl Cancer Inst, 94, 1704-11. https://doi.org/10.1093/jnci/94.22.1704
  20. Jarde T, Caldefie-Chezet F, Goncalves-Mendes N, et al (2009). Involvement of adiponectin and leptin in breast cancer: clinical and in vitro studies. Endocr Relat Cancer, 16, 1197-210. https://doi.org/10.1677/ERC-09-0043
  21. Karimi N, Roshan VD (2013). Change in adiponectin and oxidative stress after modifiable lifestyle interventions in breast cancer cases. Asian Pac J Cancer Prev, 14, 2845-50. https://doi.org/10.7314/APJCP.2013.14.5.2845
  22. Lee JJ, Park HY (2009). The timing of recurrence dependent on menopausal status after surgery for breast cancer. J Korean Surg Soc, 77, 75-81. https://doi.org/10.4174/jkss.2009.77.2.75
  23. Llanos AA, Dumitrescu RG, Marian C, et al (2012). Adipokines in plasma and breast tissues: associations with breast cancer risk factors. Cancer Epidemiol Biomarkers Prev, 21, 1745-55. https://doi.org/10.1158/1055-9965.EPI-12-0016
  24. Loi S, Milne RL, Friedlander ML, et al (2005). Obesity and outcomes in premenopausal and postmenopausal breast cancer. Cancer Epidemiol Biomarkers Prev, 14, 1686-91. https://doi.org/10.1158/1055-9965.EPI-05-0042
  25. Maccio A, Madeddu C (2011). Obesity, inflammation, and postmenopausal breast cancer: therapeutic implications. ScientificWorldJournal, 11, 2020-36. https://doi.org/10.1100/2011/806787
  26. Mantzoros C, Petridou E, Dessypris N, et al (2004). Adiponectin and breast cancer risk. J Clin Endocrinol Metab, 89, 1102-7. https://doi.org/10.1210/jc.2003-031804
  27. Mantzoros CS, Bolhke K, Moschos S, et al (1999). Leptin in relation to carcinoma in situ of the breast: a study of premenopausal cases and controls. Int J Cancer, 80, 523-6. https://doi.org/10.1002/(SICI)1097-0215(19990209)80:4<523::AID-IJC7>3.0.CO;2-C
  28. McTiernan A (2005). Obesity and cancer: the risks, science, and potential management strategies. Oncology, 19, 871-81.
  29. Miyoshi Y, Funahashi T, Kihara S, et al (2003). Association of serum adiponectin levels with breast cancer risk. Clin Cancer Res, 9, 5699-704.
  30. Nkhata KJ, Ray A, Schuster TF, et al (2009). Effects of adiponectin and leptin co-treatment on human breast cancer cell growth. Oncol Rep, 21, 1611-9.
  31. Oh SW, Park CY, Lee ES, et al (2011). Adipokines, insulin resistance, metabolic syndrome, and breast cancer recurrence: a cohort study. Breast Cancer Res, 13, 34.
  32. Ollberding NJ, Kim Y, Shvetsov YB, et al (2013). Prediagnostic leptin, adiponectin, C-reactive protein, and the risk of postmenopausal breast cancer. Cancer Prev Res (Phila), 6, 188-95. https://doi.org/10.1158/1940-6207.CAPR-12-0374
  33. Pajvani UB, Hawkins M, Combs TP, et al (2004). Complex distribution, not absolute amount of adiponectin, correlates with thiazolidinedione-mediated improvement in insulin sensitivity. J Biol Chem, 279, 12152-62. https://doi.org/10.1074/jbc.M311113200
  34. Petridou E, Papadiamantis Y, Markopoulos C, et al (2000). Leptin and insulin growth factor I in relation to breast cancer (Greece). Cancer Causes Control, 11, 383-8. https://doi.org/10.1023/A:1008903727238
  35. Porter GA, Inglis KM, Wood LA, et al (2006). Effect of obesity on presentation of breast cancer. Ann Surg Oncol, 13, 327-32. https://doi.org/10.1245/ASO.2006.03.049
  36. Ray A, Nkhata KJ, Cleary MP (2007). Effects of leptin on human breast cancer cell lines in relationship to estrogen receptor and HER2 status. Int J Oncol, 30, 1499-509.
  37. Rock CL, Flatt SW, Laughlin GA, et al (2008). Reproductive steroid hormones and recurrence-free survival in women with a history of breast cancer. Cancer Epidemiol Biomarkers Prev, 17, 614-20. https://doi.org/10.1158/1055-9965.EPI-07-0761
  38. Stattin P, Soderberg S, Biessy C, et al (2004). Plasma leptin and breast cancer risk: a prospective study in northern Sweden. Breast Cancer Res Treat, 86, 191-6. https://doi.org/10.1023/B:BREA.0000036782.11945.d7
  39. Stuckey A (2011). Breast cancer: epidemiology and risk factors. Clin Obstet Gynecol, 54, 96-102. https://doi.org/10.1097/GRF.0b013e3182080056
  40. Sung H, Choi JY, Lee SA, et al (2012). The association between the preoperative serum levels of lipocalin-2 and matrix metalloproteinase-9 (MMP-9) and prognosis of breast cancer. BMC Cancer, 12, 193. https://doi.org/10.1186/1471-2407-12-193
  41. Sweeney C, Blair CK, Anderson KE, et al (2004). Risk factors for breast cancer in elderly women. Am J Epidemiol, 160, 868-75. https://doi.org/10.1093/aje/kwh276
  42. Tworoger SS, Eliassen AH, Kelesidis T, et al (2007). Plasma adiponectin concentrations and risk of incident breast cancer. J Clin Endocrinol Metab, 92, 1510-16. https://doi.org/10.1210/jc.2006-1975
  43. Vona-Davis L, Rose DP (2007). Adipokines as endocrine, paracrine, and autocrine factors in breast cancer risk and progression. Endocr Relat Cancer, 14, 189-206. https://doi.org/10.1677/ERC-06-0068
  44. Waki H, Yamauchi T, Kamon J, et al (2003). Impaired multimerization of human adiponectin mutants associated with diabetes. Molecular structure and multimer formation of adiponectin. J Biol Chem, 278, 40352-63. https://doi.org/10.1074/jbc.M300365200
  45. Wu MH, Chou YC, Chou WY, et al (2009). Circulating levels of leptin, adiposity and breast cancer risk. Br J Cancer, 100, 578-82. https://doi.org/10.1038/sj.bjc.6604913

Cited by

  1. Adiponectin is associated with poor prognosis in carcinoma patients: evidence from a meta-analysis vol.14, pp.1, 2015, https://doi.org/10.1186/s12944-015-0157-4
  2. Cytokine and Adipokine Levels in Patients with Premalignant Oral Lesions or in Patients with Oral Cancer Who Did or Did Not Receive 1α,25-Dihydroxyvitamin D3 Treatment upon Cancer Diagnosis vol.7, pp.3, 2015, https://doi.org/10.3390/cancers7030827
  3. Association of serum adiponectin with breast cancer vol.98, pp.6, 2019, https://doi.org/10.1097/MD.0000000000014359